In a sweeping enforcement action that could impact investment in small biopharma and med-tech companies for months to come, the SEC cracked down Monday on what it labeled as a fraudulent scheme in which investors were given the impression they were reading independent, unbiased analyses on investing websites when, in reality, the writers were secretly compensated for promoting the companies' stocks.